2014-08-012024-05-14https://scholars.lib.ntu.edu.tw/handle/123456789/658105摘要：高血壓仍是目前世界最重要的疾病之一，特別是在現今的社會中，高血壓的人口節節 上升，雖然過去的研究已經知道和高血壓相關的許多心血管疾病，但是根據大規模的研 究顯示，血壓達到良好控制的比率仍然偏低。要控制好血壓有賴於生活型態的調整，以 及多種藥物的組合使用，目前研發新的電氣燒灼技術可以電燒腎臟血管的交感神經，達 到血壓控制的效果，可是目前研究仍少且不普及。另一方面，高血壓相關疾病如舒張性 心衰竭，在目前所做的研究仍不足，藥物的使用仍然是依臨床的經驗，而沒有大規模資 料庫可以作為研究。目前我們的計晝是要建立台灣的高血壓生物檢體資料庫以及臨床試驗聯盟，希望能用 合作的方式，在台灣的主要九家醫學中心，建立一個電子及資料庫收集的平台，使用共 通的資料登記軟體，臨床收集病患的共通條件，希望能完成高品質的臨床試驗。研究的 方法是在七家主要的醫學中心開始，進而推廣到其他的醫院，使用嚴格的管控，病患願 意將生物檢體提供研究之後，由各個醫院登入病患的資料到電子系統，定期由中心控管 品質，生物檢體以相同嚴格的條件存放在各家醫院中，資料庫中的病患資料，優先提供 給加入的成員使用，並可以作為日後國際的臨床研究使用，也可以提供給生物科技產業 研發新的技術，新的藥物，而改善整體國民的健康。<br> Abstract: BackgroundHypertension remains to be the most important health and public problems for the modern country. Although the influence and impact of hypertension is a well-known, the adequate control rate is low and some hypertension associated disease still lack adequate medical treatment. Successful treatment of raised blood pressure has proven elusive despite availability of various drugs, combination pharmaceutical products, and resources to assist patients’ adherence and lifestyle changes. Recently developed endovascular catheter technology enables selective denervation of the human kidney for better treatment of resistant hypertension. On the other hand, there was over half of patient with heart failure have diastolic heart failure (DHF). Hypertension could result in left ventricular hypertrophy and further diastolic dysfunction. Large randomized trials in selected patients with HF have led to major advances in the medical treatment of systolic HF. On the contrary, few randomized trials have been carried out with regard to medical management of DHF, despite its high prevalence and mortality. Therefore, treatment of DHF is still empirical and there is a scarcity of evidence-based recommendation towards the disease.Methods:To achieve the above goals, it is important to conduct multicenter trials on the treatment of hypertension associated diseases that take the advantage of more efficient screening and enrollment of cases. Specifically, we can prospectively setup a biospecimen bank with clarified disease phenotype through the conduction of these trials. The biospecimen bank and the clinical information collected from this study could also provide a platform for further investigation of cardiac diseases. We would then coordinate 9 large medical centers in Taiwan and forming a hypertension biospecimen banks, recruiting patients with hypertension, resistant hypertension, and hypertension-related cardiac disease. Through the public data bases, not only the members of the biospecimen banks could utilize the sources for fashion technology development, but international trials could also be performed. We would like to introduce a website platform to register all the patients biospecim from the medical centers in current studies. We also design 4 randomized control trials for these patients including therapies for resistant hypertension, diastolic heart failure.